Introduction {#sec1}
============

Pompe disease (glycogen storage disease type II, OMIM [232300](232300){#intref0010}) is a rare metabolic disorder that leads to progressive muscle wasting caused by acid α-glucosidase (GAA) enzyme deficiency. This autosomal-recessive disorder is caused by disease-associated variants located in the *GAA* gene.[@bib1] Classic infantile Pompe patients have a complete deficiency of GAA enzymatic activity and present hypertrophic cardiomyopathy and severe muscle weakness shortly after birth. Patients with residual GAA activity can be classified as childhood- or adult-onset Pompe patients, based on the age at symptom onset, and generally do not show cardiac involvement.

Enzyme replacement therapy (ERT) is currently the only available treatment. Without treatment, classic infantile Pompe patients do not survive the first year of life due to cardiorespiratory failure.[@bib2]^,^[@bib3] In order to become eligible for ERT, a patient needs to present a clinical phenotype related to Pompe disease and have a GAA deficiency, and certain countries require the identification of two disease-associated variants in the *GAA* gene.[@bib4] GAA activity measurements are performed using dried blood with spot sampling or with primary fibroblasts or leukocytes using either glycogen or 4-methylumbelliferone-α-d-glucopyranoside (4MU) as a substrate.[@bib5] False-positive results are known to occur using blood-based assays, for example, those caused by known pseudodeficiency alleles; therefore, DNA analysis is recommended in order to identify disease-associated variants.[@bib5], [@bib6], [@bib7] Routine diagnostic DNA analysis usually focuses only on the coding regions of *GAA* using PCR reactions and subsequent Sanger sequencing.[@bib6]^,^[@bib8] This method detects variants in the coding regions and in close proximity to splice sites but not in the promoter, UTRs, and most of the intronic regions.[@bib4]^,^[@bib9] Reported variants are listed in the "Pompe disease *GAA* variant database" (<http://www.pompevariantdatabase.nl>), which contains over 400 disease-associated variants in *GAA* and has4 recently been extended to include clinical phenotypes.[@bib10] When the disease-associated variants of both alleles are identified using DNA sequencing, a general prediction of the patient phenotype is possible using the information in this database. Recent findings indicate that analysis of the modifier c.510C\> T variant, which is silent but modulates splicing in patients carrying the common c.-32-13T\>G (IVS1) variants, is also important.[@bib11]

Previously, we described an exon-flanking RT-PCR that can be used to detect novel disease-associated variants that affect pre-mRNA splicing, irrespective of their location.[@bib9]^,^[@bib12] This assay is important for diagnosis but also to allow the design of antisense oligonucleotides that can restore splicing.[@bib12], [@bib13], [@bib14], [@bib15] Other work has shown single-nucleotide polymorphism (SNP) array analysis to be capable of explaining phenotypes by detecting large deletions or genomic copy number variations (CNVs).[@bib16], [@bib17], [@bib18] In addition, SNP array analysis can be used to elucidate homozygote variants incompatible with Mendelian inheritance by detecting uniparental isodisomies (UPDs) and regions of homozygosity (RoHs).[@bib16]^,^[@bib17]

Here, we utilized the additional diagnostic assays described above to identify the genetic cause of Pompe disease in six patients from four families with incomplete DNA sequencing results. This resulted in the identification of three novel disease-associated variants located in non-coding regions of *GAA*. Additionally, we describe the genetic analysis performed for a patient with an atypical Pompe phenotype, first described in Labrijn-Marks et al.[@bib17] We provide the clinical symptoms and the series of experiments that were performed in order to make this diagnosis and to strengthen the conclusion that this is a mosaic patient.

Results {#sec2}
=======

The six patients (including three siblings) described here had symptoms that could be attributed to a GAA deficiency. Enzymatic activity of GAA was found deficient in primary fibroblasts and indicated that Pompe disease is a probable cause of symptoms. Genetic screenings of the coding regions of GAA were insufficient to provide a genotype that corresponds with the observed phenotype ([Table 1](#tbl1){ref-type="table"}).Table 1Basic Information for All Patients at Start of AnalysisAge at Symptom OnsetGAA Activity in Fibroblasts (Patient Range: 0--20 nmol/h/mg)Disease-Associated Variant 1Disease-Associated Variant 2Initial SymptomsPatient 1\<1 month0 nmol/h/mgc.2331+2T\>A\
p.0??muscle weakness and cardiomyopathyPatient 215 years13.7 nmol/h/mgc.-32-13T\>G\
p.=, p.0??muscle weaknessPatient 3 (sibling 1)24 years7.5 nmol/h/mg? + c.2065G\>A\
? + p.(Glu689Lys)? + c.2065G\>A\
? + p.(Glu689Lys)general fatiguePatient 4 (sibling 2)41 yearsdeficient in lymphocytes? + c.2065G\>A\
? + p.(Glu689Lys)? + c.2065G\>A\
? + p.(Glu689Lys)muscle weakness and general fatiguePatient 5 (sibling 3)21 yearsdeficient in lymphocytes? + c.2065G\>A\
? + p.(Glu689Lys)? + c.2065G\>A\
? + p.(Glu689Lys)muscle weakness and general fatiguePatient 6\<1 month8.1 nmol/h/mgc.925G\>A\
p.(Gly309Arg)?left ventricular hypertrophy

Patient 1 {#sec2.1}
---------

The first indication of Pompe disease was observed during prenatal ultrasound, which found evidence of cardiac hypertrophy. Muscle weakness presented shortly after birth, and cultured primary fibroblasts showed no GAA enzyme activity ([Table 1](#tbl1){ref-type="table"}). Sanger sequencing of the coding regions identified the heterozygous c.2331+2T\>A variant ([Table 1](#tbl1){ref-type="table"}; [Figure 1](#fig1){ref-type="fig"}A). The intronic c.2331+2T\>A variant has been classified as "very severe" and is associated with the classic infantile phenotype when combined with a null allele.[@bib10]^,^[@bib19] This variant is located close to the exon 16 splice donor site and affects splicing of intron 16, ultimately resulting in a frameshift, the generation of an early stop codon, and mRNA degradation. The second disease-associated variant was not identified by standard DNA sequencing.Figure 1Identification of a Disease-Associated Deletion in Patient 1 Using the Splicing Assay(A) Genotype of patient 1 at the start of analysis. (B) Splicing assay for *GAA* exons 2--19 performed on cDNA obtained from fibroblasts. Bands marked 1. and 2. indicate two different products detected around exon 9. (C) Cartoons of products 1 and 2 identified using Sanger sequencing of the PCR product. (D) PCR product from *GAA* exon 8 to exon 10, performed on DNA. A., An additional band from patient 1 that was 343 bp smaller compared to the normal product; \*, non-specific bands as a result of the PCR. (E) Sanger sequencing of product A. The new junction resulting from the deletion is indicated. (F) Cartoon of both disease-associated variants identified in patient 1.

Exon-flanking RT-PCR for all *GAA* exons was performed as previously described[@bib9] to test for the presence of a non-coding intronic variant and revealed an aberrant product of exons 8, 9, and 10 ([Figure 1](#fig1){ref-type="fig"}B; product 2). Sanger sequence analysis of this product showed the exclusion of exon 9 from the transcripts, but it failed to identify a candidate splicing variant around the splice junctions ([Figure 1](#fig1){ref-type="fig"}C). To test the possibility of a deletion that could have been obscured by the presence of the other allele, we performed flanking exon PCR analysis of exon 9 (ranging from exon 8 to exon 10) using genomic DNA as a template ([Figure 1](#fig1){ref-type="fig"}D). This showed the presence of an additional band in the patient DNA that was not found in the healthy control, one that corresponded with the expected product ranging from exon 8 to 10 and one that contained a 343-bp deletion that spanned exon 9 and parts of the neighboring introns (band A in [Figure 1](#fig1){ref-type="fig"}E).

The resulting c.1327-61_1437+171del variant explains the exclusion of exon 9 at the RNA level and why the initial DNA sequencing analysis was unable to detect this variant, as the annealing sites for PCR amplification were included in the deleted region. The deletion of exon 9 has been shown to result in a total disruption of GAA enzyme activity in previous work.[@bib9] The combination of c.1327-61_1437+171del and c.2331+2T\>A explains the lack of enzyme activity and the classic infantile phenotype of the patient ([Figure 1](#fig1){ref-type="fig"}F).

Patient 2 {#sec2.2}
---------

The second patient presented mild muscle weakness at 15 years of age. GAA activity in fibroblasts was found to be reduced to 13.7 nmol/h/mg (patient range: 0--20 nmol/h/mg). Sanger sequencing analysis performed on the patient's DNA identified the c.-32-13T\>G (IVS1) variant in a heterozygous state but failed to identify a second disease-associated variant ([Table 1](#tbl1){ref-type="table"}; [Figure 2](#fig2){ref-type="fig"}A)Figure 2Identification of a *GAA* Promoter Deletion in Patient 2 Using a SNP Array(A) Genotype of patient 2 at the start of analysis. (B) Splicing assay for *GAA* exons 2--19 performed on cDNA obtained from fibroblasts. \*Known mis-spliced transcripts caused by the IVS1 variant. (C) Cartoon of the genomic region spanning the *CCDC40*, *GAA*, and *EIF4A3* genes in the chromosome (top) and the SNP array analysis (bottom) visualized for Chr17:78,050,000--78,120,000. Zooms are also shown on the 5′ and 3′ ends of the 17-kb deletion. (D) Sanger sequencing results around the c.596A\>G SNP using a non allele-specific PCR of DNA (top), an IVS1 allele-specific PCR of DNA (middle), and a non allele-specific PCR of cDNA obtained from fibroblasts (bottom). (E) Cartoon of both disease-associated variants identified in patient 2.

Exon-flanking RT-PCR of cDNA, derived from the patient's fibroblasts, showed no aberrant splicing products, except for those caused by the IVS1 variant around exon 2 ([Figure 2](#fig2){ref-type="fig"}B).[@bib13]^,^[@bib20]^,^[@bib21] Next, we performed SNP array analysis to test for the presence of large genomic aberrations. This analysis revealed a deletion on chromosome 17 (GRCh37/hg19 \[Chr17:78.059.821--78.076.592\]) ([Figure 2](#fig2){ref-type="fig"}C). Further evaluation of this 17kb deletion indicated that it starts upstream of *GAA* in the *CCDC40* gene and included the promoter, transcription start site (TSS), and non-coding exons 1A and 1B of *GAA*.

Formally proving the pathogenicity of this deletion was complicated, due to the residual GAA expression and activity originating from the IVS1 allele. To address this, the sequence of exon 3 in the patient's DNA and mRNA was analyzed for allele-specific SNPs ([Figure 2](#fig2){ref-type="fig"}D). We identified the c.596A\>G SNP (rs1042393, minor allele frequency \[MAF\] in Dutch population: 75%) in a heterozygous state in the patient's DNA.[@bib22] With the use of an IVS1-specific PCR ([Figure S1](#mmc1){ref-type="supplementary-material"}), we found the c.596A\>G SNP not to be present on the allele containing the IVS1 variant. Sequence analysis of the cDNA failed to detect transcripts that contained the c.596A\>G SNP, indicating that the allele containing the deletion is not expressed.

In conclusion, the 17kb deletion, including the promoter and TSS, completely abrogates *GAA* expression, and the combination with the late-onset IVS1 variant on the other allele ([Figure 2](#fig2){ref-type="fig"}E) explains the late-onset phenotype presented by the patient.

Patients 3, 4, and 5 {#sec2.3}
--------------------

Patients 3, 4, and 5 are siblings, all of whom showed progressive muscle weakness later in life. Primary fibroblasts were only available for patient 3. GAA activity in lymphocytes was deficient in all three siblings; this was confirmed in the primary fibroblasts of patient 3 ([Table 1](#tbl1){ref-type="table"}). Sanger sequence analysis revealed the 2065G\>A variant in a homozygous state for all three siblings but was unable to identify any disease-associated variants ([Figure 3](#fig3){ref-type="fig"}A). Previous work has shown that the c.2065G\>A variant reduces GAA activity to 54% in a *GAA* cDNA expression construct.[@bib23] This reduction is not sufficient for a patient to present symptoms associated with Pompe disease but is known to lead to a pseudodeficiency of GAA.[@bib23]Figure 3Identification of a RoH and a Novel Splicing Variant in Exon 1A in Patients 3--5(A) Genotype of patient 3 at the start of analysis. (B) Splicing assay for *GAA* exons 2--19 performed on cDNA obtained from fibroblasts from patient 3. (C) qRT-PCR results for *GAA* performed on cDNA obtained from fibroblasts, normalized for *GAPDH*. Significance comparing healthy control and patient 3: p \< 0.001. (D) SNP array result visualized for a segment of chromosome 17 showing absence of deletions or duplications (top) and a RoH from 17q25.3 to 17qter (bottom). (E) Sanger sequencing of exon 1, demonstrating the presence of the c.-113+2T\>A variant. (F) Cartoon of the generated constructs ranging from *GAA* exon 1A to exon 3, with the c.-113+2T\>A variant indicated. (G) qRT-PCR of *GAA* exon 2 performed on cDNA obtained from HEK293T cells after transfection with the minigene model. Results are normalized for neomycin. All comparisons were significant: p \< 0.001. (H) RT-PCRs performed on cDNA obtained from transfected HEK293T. RT-PCR ranging from exon 1b to exon 3 (left) and RT-PCR for the exon1a--1b splice junction (right). With an accompanying cartoon for the RT-PCRs, the location of the primers are indicated using arrows. (I) Cartoon of the disease-associated variant c.-113+2T\>A and the pseudodeficiency variant c.2065G\>A, both at a homozygous state in patient 3. Error bars in C and G indicate standard deviation (S.D.)

Exon-flanking RT-PCR of cDNA derived from fibroblasts of patient 3 did not detect any aberrant splicing events but showed an overall low expression of *GAA* ([Figure 3](#fig3){ref-type="fig"}B). Quantitative real-time PCR (qRT-PCR) analysis confirmed this, showing a reduction of *GAA* expression to 8% of healthy control values ([Figure 3](#fig3){ref-type="fig"}C). SNP array analysis showed several large RoHs in all siblings that were likely derived from regions that were homologous in both parents, suggesting consanguinity between the parents. Interestingly, all three siblings were found to have a RoH ranging from 17q25.3 to the 17qter (including *GAA*) but this was not present in the paternal DNA ([Figure 3](#fig3){ref-type="fig"}D; [Figure S2](#mmc1){ref-type="supplementary-material"}). The consanguinity of the parents explains the presence of the multiple RoHs in the three siblings via a combination of several identical blocks. However, this finding does not explain the decreased expression of *GAA* mRNA, and we hypothesized the presence of a variant in the 5′ UTR or the promoter. To this end, Sanger sequencing was performed for the non-coding first exons and the *GAA* promoter ([Figure 3](#fig3){ref-type="fig"}E). Sanger sequence analysis of this region revealed the presence of the homozygous variant c.-113+2T\>A in patient 3. This variant is located close to the splice acceptor of exon 1A, which is, according to recent annotations, the 5′ part of exon 1. Our unpublished RNA sequencing (RNA-seq) data indicate that in agreement with the recent annotations, exon 1 consists of two small exons (exon 1A and exon 1B) that are spliced in cells from healthy individuals, as well as patients with Pompe disease. The c.-113+2T\>A variant was also found in a homozygous state in the two siblings (patients 4 and 5) and in a heterozygous state in paternal DNA. This variant has not been described previously. DNA from the mother was unavailable.

To investigate the pathogenic nature of c.-113+2T\>A, a previously published minigene model was modified to include the genomic region of exon 1A.[@bib12] Two new constructs were generated, one wild-type and one carrying the c.-113+2T\>A variant ([Figure 3](#fig3){ref-type="fig"}F). qRT-PCR of cDNA obtained from transfected HEK293T cells using primers located in exon 2 showed that c.-113+2T\>A reduced *GAA* expression to 35% of the wild-type minigene ([Figure 3](#fig3){ref-type="fig"}G). Exon-flanking PCR for exons 1 to 3 showed that c.-113+2T\>A lowered expression of mRNA containing exon 1B-exon 3 ([Figure 3](#fig3){ref-type="fig"}H, left panel). An additional exon-flanking RT-PCR was performed to detect aberrant splicing events between exons 1A and 1B ([Figure 3](#fig3){ref-type="fig"}H). The wild-type construct spliced both exons correctly, whereas the mutant completely abolished expression of the mRNA transcript containing the exon 1A-exon 1B splice junction ([Figure 3](#fig3){ref-type="fig"}H). We note that we were unable to test these splicing events in patient fibroblasts due to the low expression of GAA mentioned previously.

In summary, the c.-113+2T\>A variant decreases expression of *GAA*. We note that the reduction in the minigene was less strong (65%) compared to the reduction in fibroblasts (92%). This difference might be due to promoter-dependent effects of the c.-113+2T\>A variant, as in the patient's fibroblasts, mRNA expression is regulated by the endogenous *GAA* promoter, whereas expression from the minigene model is regulated by the cytomegalovirus (CMV) promoter. Additionally, all three patients carry both the c.-113+2T\>A and c.2065G\>A variants at a homozygous state ([Figure 3](#fig3){ref-type="fig"}I). The c.2065G\>A missense variant is known to decrease activity to ∼50%.[@bib23] The combined action of both variants likely reduces endogenous GAA activity to pathogenic levels.

Patient 6 {#sec2.4}
---------

Indications for a superior vena cava syndrome were found during a routine prenatal ultrasound. Further cardiac screening was performed at the age of 2.5 months and revealed a left ventricular hypertrophy (LVH) with cardiac ultrasound, whereas electrocardiography showed a shortened PQ interval time without signs of pre-excitation ([Table 2](#tbl2){ref-type="table"}). At this time, the patient was normotonic with good psychomotor development and showed no signs of muscle weakness. Exome screening of cardiac genes was negative, and a metabolic examination of plasma and urine showed mildly elevated creatine kinase (CK) and transaminase levels. GAA activity was found to be only slightly decreased in leukocytes, whereas in primary fibroblasts, enzymatic activity was within the range of late-onset Pompe disease ([Table 2](#tbl2){ref-type="table"}).[@bib17] Histochemical analysis of a muscle biopsy showed normal morphology, but some enlarged lysosomes were visible using acid phosphatase staining ([Figure S3](#mmc1){ref-type="supplementary-material"}). In addition, periodic acid-Schiff (PAS) staining showed minor glycogen accumulation ([Figure S3](#mmc1){ref-type="supplementary-material"}). These findings suggested that the patient might have late-onset Pompe disease,[@bib24] but there were two inconsistencies: the lack of GAA deficiency in lymphocytes and the LVH, a characteristic of the classic infantile phenotype but not late-onset Pompe disease. Sanger sequencing revealed only the disease-associated variant c.925G\>A at a heterozygous state ([Figure 4](#fig4){ref-type="fig"}A). This variant is associated with the classic infantile phenotype when combined with a null allele.[@bib25]^,^[@bib26] Sanger sequence analysis of the parents (both showed no signs of Pompe disease) found the c.925G\>A only in a heterozygous state in paternal DNA. No other disease-associated variants were identified in the patient nor in his parents ([Table 2](#tbl2){ref-type="table"}). Exon-flanking RT-PCR of cDNA from primary fibroblasts of the patient did not detect any splicing aberrations ([Figure 4](#fig4){ref-type="fig"}B). Sequence analysis of the *GAA* mRNA transcripts showed that the majority of transcripts contained the c.925G\>A variant ([Figure 4](#fig4){ref-type="fig"}C). This indicated that the second *GAA* allele was present but was expressed at reduced levels. SNP array analysis identified a 39.5-Mb allelic imbalance, ranging from 17q21.31 to the 17qter ([Figure 4](#fig4){ref-type="fig"}D).[@bib17] The imbalance showed no change in CNV but a change in chromosomal equilibrium (i.e., a change in the B allele frequency of heterozygous SNPs) for SNPs located in the affected segment.[@bib17] Within the imbalanced segment, *GAA* was present, whereas all other genes present within this region were unlikely to be the cause of the presented phenotype ([Table S1](#mmc1){ref-type="supplementary-material"}).[@bib27] When analyzing the SNP array data, it became clear that the allelic imbalance was more profound in fibroblasts compared to leukocytes. We estimated a deviation in B allele frequency (ΔBAF) of ±25% in fibroblasts compared to ±17% in leukocytes ([Figure 4](#fig4){ref-type="fig"}D). This was consistent with the GAA activity, which showed that activity in fibroblasts was lower compared to leukocytes ([Table 2](#tbl2){ref-type="table"}).Table 2Clinical and Molecular Information Accompanying Patient 6Patient InformationAge at analysis2.5 months to 4 yearsGendermaleGAA ActivityPatient RangeFibroblasts8.1 nmol/h/mg0--20 nmol/h/mgLeukocytes26 nmol/h/mg0--10 nmol/h/mgClinical DescriptionLeft ventricular hypertrophy detectedNo signs of respiratory insufficiencyNo muscle weaknessCardiac Muscle MeasurementsLeft ventricular mass122.1 g (*Z* score +3.7)Shortening fraction37.1% (*Z* score +0.14)CK levels243 U/L (ref \< 230 U/L)Disease-Associated VariantsAllele 1c.925G\>AAllele 2no variant foundParental Disease-Associated VariantsFather (Asymptomatic)Allele 1c.925G\>AAllele 2no variant foundMother (Asymptomatic)Allele 1no variant foundAllele 2no variant foundSNP Array ResultSegmental abnormality range: Chr17:41.681.527--Chr17qterFigure 4Identification of a Mosaic Segmental UPD in Patient 6(A) Genotype of patient 6 at the start of analysis. (B) Splicing assay for *GAA* exons 2--19 performed on cDNA obtained from fibroblasts. (C) Sanger sequencing around the c.925G\>A variant performed on cDNA obtained from fibroblasts. (D) SNP array analysis of chromosome 17 performed on DNA obtained from leukocytes (top) or fibroblasts (bottom). ΔBAF indicates the estimated difference in BAF between the affected and unaffected segment. (E) Sanger sequencing around the 925G\>A variant performed on DNA obtained from leukocytes (top), fibroblasts (middle), or skeletal muscle tissue (bottom). (F) FISH analysis performed in fibroblasts showing probes located on 17p12 (green) and 17q22 (red) and 4′,6-diamidino-2-phenylindole (DAPI) staining to highlight the cell nucleus. A representative image is shown, and a quantification is given below the figure. (G, top) Biochemical quantification of GAA activity measured using 4MU as a substrate. Significance comparing patient 6 and all other samples: not significant. Significance comparing classic infantile and healthy control: p = 0.01. (G, bottom) Measurements of intracellular glycogen. Significance comparing classic infantile versus the childhood, adult, and healthy control samples: p \< 0.01. Comparison of patient 6 and all other samples: not significant (patient 6 versus healthy control: p = 0.052). Both assays were performed on the same protein extracts obtained from fibroblasts after culturing to confluence for 3 weeks, followed by a 24h starvation to clear intracellular glycogen. GAA activity is shown as a percentage of the healthy control fibroblasts. (H) Cartoon of both disease-associated variants identified in patient 6. Error bars in G indicate S.D.

Additional Sanger sequence analysis of the patient's tissues showed a skewed contribution in favor of the c.925A variant in primary fibroblasts, leukocytes, and also in skeletal muscle tissue ([Figure 4](#fig4){ref-type="fig"}E). Microsatellite analysis of chromosome 17 showed a skewed composition in favor of the paternal allele in the affected segment, whereas markers located in the unaffected segment were distributed evenly ([Figure S4](#mmc1){ref-type="supplementary-material"}). Fluorescence *in situ* hybridization (FISH), using probes located on 17p12 and 17q22 to detect both ends of chromosome 17, showed a normal karyotype in the patient's fibroblasts ([Figure 4](#fig4){ref-type="fig"}F). Both ends of the chromosome were present at equal numbers, confirming that this imbalance is not the result of a change in genomic copy number.

The results are in line with a mosaic segmental UPD, in which affected cells contain two copies of the paternal *GAA* that harbor the c.925G\>A variant. The patient's tissue is comprised of two distinct cell populations: one with the c.925G\>A variant in a homozygous state, resulting in a classic infantile Pompe genotype, and one with the c.925G\>A variant in a heterozygous state, which results in a healthy cell population. To confirm this further, two protein-based assays were performed to examine the biochemical properties of the patient's cells. [Figure 4](#fig4){ref-type="fig"}G shows the results of the glycogen accumulation and GAA activity assays, which were performed on the same cellular extract. Patient fibroblasts accumulated intracellular glycogen, a characteristic that normally only occurs *in vitro* in fibroblasts derived from classic infantile Pompe patients but not in late-onset patients. However, GAA enzymatic activity ([Figure 4](#fig4){ref-type="fig"}G) was present and in the range of late-onset Pompe disease. This is in agreement with a genetic mosaicism with the sample consisting of two cell populations: one that accumulates glycogen *in vitro* and one that still possesses enzymatic GAA activity and thereby does not accumulate glycogen.

In summary, the atypical phenotype for Pompe disease presented by patient 6 can be explained by a genetic mosaicism for a segment of chromosome 17 that includes *GAA*. It is likely that in cardiac cells, the contribution of homozygous cells to heart tissue is relatively large, causing a LVH. In skeletal muscle cells, the mixture of homozygous and heterozygous nuclei in muscle fibers likely causes only mild pathology.

Discussion {#sec3}
==========

Conventional diagnostic procedures are able to identify and diagnose most individuals with Pompe disease; however, a number of cases remain unexplained.[@bib4] Here, we emphasize the need to introduce new methods in the diagnostic validation of Pompe disease in cases for which conventional procedures prove insufficient. With the use of extended diagnostic analyses, we identified three new variants in the *GAA* gene. With the use of minor adjustments to already-existing assays, we proved the pathogenicity of the variants and completed the diagnosis for six cases of Pompe disease derived from four families ([Table 3](#tbl3){ref-type="table"}).Table 3Novel Variants Identified with Proof of PathogenicityDisease-Associated Variant on Allele 1Disease-Associated Variant/Event on Allele 2Proof of Pathogenicity for Novel VariantPatient 1c.2331+2T\>Ac.1327-61_1437+171del[a](#tblfn1){ref-type="table-fn"}resulting deletion in the transcript is known to cause a deficiency of *GAA*Patient 2c.-32-13T\>G17 kb deletion, including promoter and transcription start site of *GAA*[a](#tblfn1){ref-type="table-fn"}no RNA expression originating from the allele containing the deletionPatients 3, 4, and 5c.-113+2T\>A[a](#tblfn1){ref-type="table-fn"}\
+ c.2065G\>A[b](#tblfn2){ref-type="table-fn"}c.-113+2T\>A[a](#tblfn1){ref-type="table-fn"}\
+ c.2065G\>A[b](#tblfn2){ref-type="table-fn"}expression and splicing analysis of variant in minigene modelPatient 6c.925G\>Amosaicism c.925G\>A[a](#tblfn1){ref-type="table-fn"}SNP arrays of different tissues, Sanger sequencing, glycogen accumulation assay[^1][^2]

In previous work, the exon-flanking RT-PCR analysis proved useful to identify novel variants located outside the coding regions, for example, as shown by the identification of c.2190-345A\>G.[@bib9] Here, we showed this assay to be capable of detecting novel deletions and revealing differential gene expression as a result of *GAA* variants. However, the 17kb deletion in patient 2 and thereby other deletions spanning more than one exon remained undetected, and additional assays were required. To detect the deletion of exon 18, which is a common variant in Caucasian patients with Pompe disease, our diagnostic center performs a separate PCR reaction.[@bib28] However, other large deletions are not routinely analyzed and will therefore not be identified. This is supported by the under-representation of gross deletions and other types of variants, such as promoter variants in *GAA.*[@bib10]^,^[@bib29]^,^[@bib30] As described in the Human Gene Mutation Database (HGMD), gross deletions represent 7.5% of all disease-associated variants, whereas approximately 1% of all disease-associated variants are reported to be located in promoter regions genome wide.[@bib29] For Pompe disease, gross deletions constitute only 1.5% of known variants, and the variants described here in patients 2 and 3 represent the first reported disease-associated variants located in the promoter and 5′ UTR regions of *GAA.*[@bib10] These regions are critical for the regulation of gene expression, and we recommend these regions to be included in future diagnostic analyses. The detection of non-coding variants can be improved with the implementation of techniques already established in many diagnostic laboratories as a follow-up to DNA sequencing. SNP array analysis allows for the detection of large deletions or duplications, whereas aberrant splicing events or severe reductions in gene expression can be detected using whole transcriptome sequencing.[@bib18]^,^[@bib31] Other existing techniques can also be implemented for specific monogenic disorders and are capable of detecting smaller aberrations. Multiplex ligation-dependent probe amplification (MLPA) can detect deletions affecting single exons, whereas exon-flanking RT-PCR can be performed to detect deletions, splicing aberrations, and differential gene expression.[@bib9]^,^[@bib18] A more systematic approach, as described above, could lead to the identification of new disease-associated variants and provide a complete DNA diagnosis for patients. The implementation of the approaches outlined here should therefore be considered to improve the genetic analysis of cases with an unexplained genetic diagnosis.

Patients with an atypical phenotype often represent a challenge when diagnosing genetic disorders. Patient 6 presented a unique pathological condition: LVH, a characteristic usually observed only in the classic infantile phenotype, while lacking any sign of muscle weakness after 4 years of age. This phenotype was corroborated by the differences in GAA activity in the patient's tissues. With the use of the SNP array analysis, we detected a chromosomal imbalance on chromosome 17, which was crucial to identify the genetic mosaicism of Pompe disease. Genetic mosaicisms are often associated with a milder symptomatology due to the presence of a healthy or less affected cell population.[@bib32]

The mosaicism in patient 6 appears to be the result of a segmental UPD. UPDs have been associated with many inherited disorders and appropriately explain a subset of patients carrying homozygous disease-associated variants.[@bib33] Whole-chromosome UPDs are reported to occur in 1/3,500 births,[@bib33] whereas segmental UPDs occur less frequently and are the result of somatic recombination.[@bib34], [@bib35], [@bib36] The mosaic nature of the segmental UPD and the high percentage of affected cells in several of the patient tissues suggest that the recombination event occurred early in the postzygotic stage of embryonal development.[@bib34], [@bib35], [@bib36] Tissues of this patient were thereafter comprised of two cell populations, with the c.925G\>A disease-associated variant being present at either a heterozygous (healthy) or homozygous (classic infantile) state.

The presence of a population of healthy cells in the patient did not prevent the development of LVH, which normally only occurs in classic infantile patients. However, at 4 years of age, the patient has not yet manifested any other symptoms related to Pompe disease. The lack of muscle weakness in this patient was reflected by mild pathology in his muscle biopsies. This is likely due to the multinucleation of muscle fibers, whereby the genetic mosaicism in this patient is offset by the presence of both affected and unaffected nuclei in individual muscle fibers, which could be sufficient to prevent muscle pathology. A comprehensive follow-up of this patient, including CNS magnetic resonance imaging (MRI) and neuropsychological investigations, will be required to rule out additional symptoms, such as white matter changes in the brain, which can manifest in classic infantile Pompe patients.[@bib37]^,^[@bib38]

This study shows the need for the implementation of additional diagnostic assays and research as a follow-up when conventional procedures prove insufficient or when a patient's symptoms or biochemical characteristics do not match to a disorder. For monogenic disorders, such as Pompe disease, more specific assays can be implemented for an improved analysis of a singular gene. The implementation of this follow-up will likely result in the identification of novel variants and provide a complete DNA diagnosis for patients carrying non-coding variants.

Materials and Methods {#sec4}
=====================

Patients {#sec4.1}
--------

The patients described here were selected for their clinical and/or biochemical diagnosis that could be attributed to a deficiency of GAA. Informed consents were obtained to perform extended diagnostic assays to identify *GAA* variants and explain the presented phenotypes. Analysis of the patients analyzed in this study was approved by the medical ethics committee of the Erasmus MC. Primary fibroblasts were not available for patient 4 and 5, assays were performed for patient 3, and findings were thereafter confirmed in DNA from patients 4 and 5.

DNA Analysis {#sec4.2}
------------

GenBank: [NM_001079803.2](ncbi-n:NM_001079803.2){#intref0020} and [NM_0001079803.2](ncbi-n:NM_0001079803.2){#intref0025} were used as reference sequences for *GAA* DNA and mRNA, respectively, where c.1 represents the first nucleotide of the translation start codon ATG. NP000143.2 was used as a reference for GAA protein. We note that in previous annotations, exon 1 comprised 334 nt, whereas in current annotations, this region is divided into two exons (exon 1A and 1B) and a 185-nt intron. All SNP arrays analyses were performed using the Illumina Infinium CytoSNP-850K BeadChip platform. Analysis of genes related to genetic disorders located within specified genomic regions was performed using Genomic Oligoarray and SNP Array Evaluation Tool v3.0.

Histology and Imaging {#sec4.3}
---------------------

Acid phosphatase staining was performed on cryosections, as described.[@bib39] PAS staining was performed on sections of glycolmethacrylate (GMA)-processed tissue.[@bib24] Hematoxylin and eosin (H&E) stainings were performed on both GMA fixated and cryosections. A Hamamatsu NanoZoomer 2.0 (Hamamatsu Photonics) was used for imaging, and images were analyzed with NDP.view software.

RNA Isolation and cDNA Synthesis {#sec4.4}
--------------------------------

Total RNA was isolated from cultured fibroblasts using the RNeasy minikit (QIAGEN), including a DNaseI (QIAGEN) treatment. RT-PCR was performed using the iScript cDNA synthesis kit (Bio-Rad) in reactions with 300--800 ng RNA input.

PCR and Sanger Sequencing {#sec4.5}
-------------------------

RT-PCR and qRT-PCR were performed as described.[@bib9] Sanger sequencing of PCR products was performed using a ABI3730XL DNA analyzer (Thermo Fisher Scientific) and analyzed using ApE software.

Generation of the Minigene Constructs and Transfection {#sec4.6}
------------------------------------------------------

The minigene model described in Bergsma et al.[@bib12] was modified as follows: with the use of a primer with a XhoI overhang and a SBF1 restriction site, the exon 1a region was amplified and cloned in the construct. We used the QuikChange II Site-Directed Mutagenesis Kit (Agilent Technologies) to introduce the c.-113+2T\>A variant. Transfection of the minigene constructs was performed in HEK293T cells using Lipofectamine 2000 (Invitrogen). RNA was harvested 48 h after transfection.

Enzyme Activity and Glycogen Assay {#sec4.7}
----------------------------------

GAA activity was measured in leukocytes or fibroblasts using 4MU, as described.[@bib9] All 4MU assays were performed in diagnostic settings, with the exception of [Figure 4](#fig4){ref-type="fig"}G. For this experiment, fibroblasts had been confluent for 3 weeks and starved in glucose-free medium, 24 h before harvest, after which, GAA activity was measured using the 4MU.[@bib9] Intracellular glycogen was measured with a two-step protocol using amylase and glucose-oxidase.[@bib9]

Fragment Analysis of Microsatellite Markers {#sec4.8}
-------------------------------------------

15 probes were selected for their location on chromosome 17. Analysis of the VIC- or FAM-labeled products was performed using an ABI3730XL DNA analyzer (Thermo Fisher Scientific).

Fluorescence *In Situ* Hybridization Analysis {#sec4.9}
---------------------------------------------

FISH was performed on cultured fibroblasts at a low passage number. Two probes located on 17p12 and 17q22 were used to visualize both ends of the chromosome. The cells were not confluent when fixed and classified as having a normal karyotype when two or four copies of each probe were visible.

Statistics {#sec4.10}
----------

Data were analyzed using IBM SPSS statistics, version 26. For all experiments, normal distribution of data was determined based on calculated residuals. Significance between normally distributed data from two groups was tested using an unpaired two-tailed t test. For experiments with three or more groups, a one-way ANOVA of independent samples with Tukey honestly significant difference (HSD) or Games-Howell post hoc multiple correction (depending on homogeneity of the variance) was performed. Non-normal distributed data were statistically tested using the Kruskal-Wallis method of independent samples with Bonferroni multiple comparison for three or more groups. A p value of less than 0.05 was considered significant for all tests.
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[^1]: Novel variants.

[^2]: Pseudodeficiency variant.
